What is the efficacy of fruquintinib as a later‑line treatment in patients with metastatic rectal cancer who have progressed after fluoropyrimidine‑based chemotherapy (including oxaliplatin and irinotecan) and prior anti‑VEGF or anti‑EGFR therapy?

Fruquintinib Efficacy in Metastatic Rectal Cancer

Fruquintinib demonstrates significant survival benefit in heavily pretreated metastatic rectal cancer, improving overall survival by 2.6 months (7.4 vs 4.8 months, HR 0.66, P<0.0001) in patients who have exhausted all standard therapies including prior anti-VEGF and anti-EGFR treatments. 1, 2

Evidence Base and Patient Population

The efficacy of fruquintinib is established through two pivotal phase III trials (FRESCO-2 and FRESCO) that specifically enrolled patients with metastatic colorectal cancer (which includes rectal cancer) who had progressed through extensive prior therapy 1, 2, 3.

FRESCO-2 Trial (Global, Most Recent):

• 691 patients across 14 countries, 124 centers
• Median 4 prior lines of systemic therapy (73% received >3 lines)
• 97% had prior anti-VEGF therapy
• 91% had received trifluridine-tipiracil, 48% regorafenib, 39% both
• Median OS: 7.4 months vs 4.8 months placebo (HR 0.66,95% CI 0.55-0.80, P<0.0001)
• Median PFS: 3.7 months vs 1.8 months placebo (HR 0.32, P<0.0001) 2, 3

FRESCO Trial (China):

• 416 patients, less heavily pretreated (30% prior anti-VEGF)
• Median OS: 9.3 months vs 6.6 months placebo (HR 0.65, P<0.001)
• Median PFS: 3.7 months vs 1.8 months placebo (HR 0.26, P<0.001) 2

NCCN Guideline Recommendation

The NCCN 2024 guidelines explicitly recommend fruquintinib as a treatment option for metastatic colorectal cancer (including rectal) that has progressed through all other available regimens. 1

Key positioning:

• Can be given before or after trifluridine-tipiracil (with or without bevacizumab) or regorafenib
• No data inform the optimal sequencing of these late-line agents
• Only 20% discontinued fruquintinib due to toxicities, suggesting good tolerability 1

Safety Profile

The toxicity profile is manageable and consistent with VEGFR inhibition:

• Grade ≥3 adverse events: 63% (vs 50% placebo)
• Most common Grade ≥3 events:
  • Hypertension: 14%
  • Asthenia: 8%
  • Hand-foot syndrome: 6%
• Treatment-related deaths: rare (1 patient with intestinal perforation in FRESCO-2) 1, 3

Clinical Application Algorithm

Use fruquintinib when:

1. Patient has metastatic rectal cancer with progression after:

   • Fluoropyrimidine-based chemotherapy (5-FU or capecitabine)
   • Oxaliplatin-based regimen
   • Irinotecan-based regimen
   • Anti-VEGF therapy (bevacizumab, aflibercept, or ramucirumab)
   • Anti-EGFR therapy if RAS wild-type (cetuximab or panitumumab)

2. ECOG performance status 0-1

3. Adequate organ function and blood pressure control (exclude if systolic BP >140 or diastolic >90 mmHg, urine protein ≥1 g/24h) 2

Dosing: 5 mg orally once daily, days 1-21 of each 28-day cycle, until progression or unacceptable toxicity 2

Important Caveats

• No specific biomarkers predict fruquintinib response - efficacy was consistent across RAS mutation status (63% RAS-mutant in FRESCO-2) 3
• The survival benefit is modest but clinically meaningful in this heavily pretreated population with limited options
• Real-world data suggest potentially superior outcomes compared to trial data, with median OS of 12.6 months in some cohorts 4
• Brain metastases, declining skeletal muscle index (>5% decrease), and elevated baseline CEA may predict worse outcomes 4

Comparative Context

While direct head-to-head comparisons are lacking, fruquintinib appears comparable to regorafenib and trifluridine-tipiracil in efficacy, with potentially better tolerability (only 20% discontinuation rate vs higher rates with regorafenib) 1, 5. The choice between these agents should be based on individual patient factors, prior exposures, and toxicity profiles rather than efficacy differences.